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Abstract--Most clinical activities (e.g. diagnosis and prognosis~ implicitly assume some 
definition or interpretation of disease in order to provide a means for generating ex- 
planatory and predictive hypotheses. These serve as a basis for describing and treating 
patients. This paper discusses two models designed to identify and characterize ho- 
mogeneous subgroups of patients, based upon analysis of large scale chronic disease 
data banks. From consideration of the formulation of these models, we suggest hat 
the evaluative tasks broadly labeled diagnosis and prognosis involve the rigorous and 
precise definition of the patient's disease. The models also reveal a duality in the quan- 
tification of clinical judgment involved in the simultaneous description of diseases and 
patients. An illustration from the study of Systemic Lupus Erythematosus is provided. 
It is concluded that both models have significant implications for future research, in- 
cluding the detailed study and modeling of chronic disease spectra, clinical decision 
making and the analysis of applied judgmental processes. 
I. INTRODUCTION 
This paper presents two models designed to assist clinicians by quantitatively portraying 
the clinical history (or course) of disease. Here illness is schematicized as a dynamic 
process, chronologically developing and evolving on different levels. The term history is 
used to denote the joint range of observable manifestations of a disease, from onset of 
the basic lesion to initial indicant (signs, symptoms, etc.) production, through secondary 
and multisystemic involvement. The models described here identify and characterize clin- 
ically significant points along the history. A set of such points is called a disease spectrum. 
They provide means for describing patients, and thereby serve as precise, de fitcto defi- 
nitions of disease and illness. 
2. CL IN ICAL  BACKGROUND 
Consider the point at which a patient enters the health care delivery process, in con- 
fronting the patient's illness, the clinician is faced with two evaluative tasks. The first 
concerns identifying the disease responsible for the patient's presenting condition. This 
is equivalent o specifying a label for the disease, a procedure generally called differential 
diagnosis. 
* Author to whom correspondence should be addressed. 
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In accomplishing this, which may include taking a detailed medical history'of the pa- 
tient, the provider is in effect attempting to recreate the natural history, or past, unob- 
served portion of the disease course. (The unobserved portion of the disease history is 
called the natural history, since it generally does not entail therapeutic intervention; there- 
after, the disease history or course is not genuinely "natural.") Several diseases may be 
hypothetical explanatory choices. Some may be eliminated from consideration following 
observation of a pathognomic marker or markers. Failing that, competing choices may 
be pared using, for example, a decision-theoretic algorithm. 
The second matter of concern to the physician is generally called prognosis and involves 
treating the illness (or, if that is not possible, treating the indicants). The formulation of 
predictive clinical hypotheses i a prominent feature of this clinical activity. Thus pre- 
dictive hypotheses deal with such issues as estimating the course of a patient's illness 
(e.g. whether the patient will get better or worse) and ways to affect that course (e.g. 
therapeutic interventions). From this perspective, the clinician is attempting to predict 
the general future history of the disease course, and the direction and momentum traveled 
by the patient along the alternative paths describing that future history. In the sense that 
prognosis involves disease outcomes, it may be sequentially modified over time as dif- 
ferent therapeutic strategies are invoked. 
Thus the tasks of clinical judgment can be partitioned into two parts. The first subtask 
corresponds to the initial physician/patient encounter and entails the diagnostic aspects 
of the clinician's task. Here a set of causal possibilities is winnowed by appropriate se- 
lection and implementation of tests, history taking and other judgmental activities. The 
second clinical subtask involves specifying a sequence of potential trajectories that may 
represent the course of the patient's illness, starting at the point of initial observation. 
In the sense that patient management is continuous (especially in the case of long-term, 
chronic illness), the activities discussed above may be regarded as a cross-section of a 
sequential, ongitudinal process. For example, at a followup encounter (say time 2). the 
physician may assess the course of the patient's illness between the previous visit (say 
time 1) and the current point of observation. Predictive hypotheses (time I) yield to new 
explanatory hypotheses (time 2). Charting the patient's progress may necessitate the gen- 
eration of revised predictive hypotheses in the light of new evidence (time 2), corre- 
sponding to changes in the disease. Thus there is a clear duality between the role of 
explanatory and predictive hypothesis generation. 
3. DISEASE DEFINITION 
In formalizing explanatory and predictive hypotheses, the clinician relies on some defi- 
nition of disease. Disease definition is used here in an operational, rather than a purely 
ontological sense. For purposes of this discussion, a disease is regarded as a primary 
lesion or primitive causal mechanism; for example, an infection, an ulceration[l-3]. The 
patient's illness is his response to the disease, which can vary widely within patients over 
time and among patients at all points. The explanatory and predictive clinical hypotheses 
described earlier represent an effort to define related constellations of indicants and es- 
tablish causal interpretations of these relations[4]. 
The conventional source of input for disease definitions lies in the intersection of the 
so-called "existing body of medical knowledge," and the experience and background of 
the individual physician. The former usually consists of descriptions of disease as "classic 
textbook cases," as well as noteworthy departures from the usual clinical picture[5]. 
Experience nables the clinician to fine tune his ability to detect variations in the standard 
clinical picture of disease and to more readily perceive a disease in a common clinical 
form[6]. 
Global models of disease 1139 
The disease definitions that arise from these objective (knowledge) and subjective (judg- 
mental) sources are subject to a lack of precision and rigor. Precision may be lacking 
because many clinical indicants are omitted from consideration, while rigor may be absent 
owing to the lack of a suitably large or valid patient pool for purposes of comparison. 
Thus conventional disease taxonomy groups patients crudely, obscuring subtle but 
potentially important clinical differences among patients[7, 8]. In addition, the task of 
hypothesis generation is left to the clinician. Clinicians. in turn, may vary widely in the 
judgments they form regarding a patient's condition or need for treatment[6, 9. 10]. 
A cursory evaluation of the current state of health care delivery strongly suggests that 
profound external forces are acting to influence and modify the nature of disease definition. 
Perhaps the foremost of these influences is the rapid development and proliferation of 
medical information systems[1 I]. These health and disease data resources have emerged 
as routine facilities in hospitals, academic health centers and health insurance organi- 
zations; they make feasible the acquisition, storage and retrieval of extensi``'e patient data 
for a wide class of diseases. 
In fact, the explosive growth of computerized patient data banks has spav,'ned an entire 
academic discipline. Medical Informatics[12]. This new field of study has as its foci the 
design, implementation a d utilization of sophisticated computerized patient data banks. 
These data sources not only feature extensive profiles of patients with well-defined is- 
eases, but information describing "'normal" patients, those with no identifiable patho- 
logical condition who may, for example, present for routine physical examination. Thus. 
as examination of data on nondiseased patients proceeds, new concepts of normality may 
arise; these, in turn, may imply revised concepts of ill-health or disease. 
Still another external influence on disease definition is the accelerating increase in the 
volume and detail of medical knowledge. This has resulted from a broad range of activities. 
from laboratory research to epidemiological field surveys, to experiments in alternative 
health care delivery systems. Consequently, disease manifestations can be observed on 
levels ranging from the subcellular to the multisystemic. In addition, one finds new in- 
formation concerning the precursors of disease (e.g. risk factors), as ,,,,'ell as the response 
to disease. 
In sum, then, the qualitative deficiencies of conventional disease definition coupled 
with the increase in the volume and nature of disease descriptors indicates the need for 
new methods of inquiry for defining disease. Improving the precision, sensitivity and 
specificity of the identification of homogeneous subsets of patients will yield correspond- 
ing improvements in the rigor and precision with which explanatory and predictive clinical 
hypotheses can be constructed and formalized and the clinical spectra of disease 
explicated. 
To this end, the subsequent sections of this paper describe two mathematical models 
we have derived to provide means for defining disease. Although these models deal sep- 
arately with matters of diagnosis and prognosis, there is nonetheless a conceptual iso- 
morphism between the tv,'o which will become apparent as the discussion proceeds. 
4. IMPLICANT MODEL OF DISEASE (DIAGNOSIS) 
Most researchers in the area of disease models are familiar with the use of Bayes's 
theorem. Briefly, given first, a set of mutually exclusive and exhaustive disease states 
D~, D, . . . . .  D,, ; second, associated prior probabilities (incidence stimates)P(Di), i = 
1, 2 . . . . .  n; third, a vector of clinical indicants X = (.v~, x: . . . . . .  v,,,); and fourth. 
estimates of conditional probabilities of the form P(X  ] Di); then the estimated posterior 
conditional probability of disease Di is given by 
P(D i  I X )  = P (D, )P (X  I D , /E ,P (D/ )P (X  I Dj). (l) 
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The limitations o f / l )  in diagnostic ontexts have been well documented[13-15]. In 
particular, the elements of X may not be conditionally independent, and patients may 
have more than one disease: both of these circumstances make deriving estimates of the 
form P(X I D~) difficult if not impossible. In addition, PIX i Dj) may vary depending on 
the patient's position in the course of disease j. Equation (1) models the decision making 
process, not the disease process. The definitions of the Dj are implicit in (1): yet the very 
attributes of the disease definitions may invalidate the use of (1). {Indeed, since its original 
inception, the use of decision-theoretic models in health care delivery has generally be- 
come more specific and limited in scope, such as deciding whether or not to order a given 
test[16]. In addition, models based on (1) above have proven useful in schematicizing the 
decision-making and information-utilization process in forming diagnostic linical judg- 
ments and in explicating the patient evaluation procedures of experienced clinicians[ 17].} 
The Implicant model defines disease in terms of fundamental disease components 
called, appropriately enough, implicants. The implicants are assumed to be independent 
with respect o indicant production (the noninteractive hypothesis). A disease is defined 
in terms of the label attached to a collection of implicants. The presence of an implicant 
is usually latent and must be inferred probabilistically. 
Consider a set of patients, each with a given set of indicant outcomes: assume these 
outcomes are binary. Define an indicator andom variable x,v to be one if the ith patient 
has indicant j, and zero otherwise. Define the unknown indicator :.;k to be one if the kth 
imnplicant is a disease component of the ith patient, and zero otherwise. The noninter- 
active hypothesis implies that indicantj will occur if at least one of the implicants present 
produced it: hence it will not occur if and only if none of the implicants present produced 
it. Functionally. given a collection of implicants Z and some indicant xj, this may be 
written as 
P(x i [Z)  = 1 - P(-v/IZ) 
= l -  1-I [ l -  P(-V;I :.)1, (2) 
where : ;  is a component implicant of Z, :{j is the set-theoretic complement of a:,-. and the 
Greek letter Fl denotes product. 
Equation (2) implies that a disease, here labeled D, defined as an indexing set equivalent 
to a collection of implicants, is a latent class in the sense of Lazarzsfeld and Henry[18]. 
That is, the implicants are not defined a priori: only the indicants are observed a priori. 
The implicants are latent within the indicant data. An illustration of this notion is provided 
by' Warner in [19]: 
It is not possible to calculate the probability of a disease combination from data on the 
incidence of symptoms in each of the separate diseases. To illustrate the point, consider 
the two diseases, pulmonary stenosis and atrial septal defect. Since neither of these 
diseases alone will produce cyanosis, it would be impossible to predict just from the 
incidence of cyanosis in the independent lesions that a patient with both lesions might 
present with cyanosis. Thus, pulmonary stenosis plus atrial septa[ defect must be con- 
sidered a new disease entity. 
Given D. we assume that 
P(D) = 1-I P(d) (3) 
d~D 
and that 
PIX I D) = 1-[ P(x; I D). (4) 
i 
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We wish to define a set of implicants uch that t2), (3) and (4) are valid. Note that such 
a set of implicants also validates the use of{ 1) in a diagnostic ontext: that is. the diseases 
defined by collections of implicants are independent and not mutually exclusive. The use 
of (4) validates the conditional probability estimates derived by the model. 
4.1. Model computation 
In this section, we outline an approach to obtaining probability estimates of implicant 
presence, given a set of patient indicant data. Full details of the procedure, together with 
an illustration, are presented in [13]. 
Let i index a patient, and let x and z denote an arbitrary indicant and implicant re- 
spectively. Denote the probability that the kth implicant by itself produces indicant j by 
B ik. Let pk denote the frequency of the kth implicant pattern. Then 
PI.r,. :,) = I I  H [Fl L1 - H 
k .i k k 
where as before, i-f, i = 1 - ,rij. Rearranging terms yields 
P(.r,. =.,) = {H [fk H (Bi~)""I ''~} {H [I - H (Bi~):'~l""} • 
k ] .i /, 
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Denote the two expressions within the square brackets in (6) by Q~ and Q:. respectively. 
Note that Q~ and Q2 are confined to the closed unit interval. Q~ represents the likelihood 
for implicants assumed to be present; Q: the same for those assumed missing. The principal 
computational chore is to evaluate Q2. since we want to assume that no significant im- 
plicants are overlooked. 
Define a bounding factor by 
b,, = 1-I (Bi ) 
J 
Then 
P(xi. :~) -< I-[ (ba):'~" (7) 
k 
The bounding factors correspond to implicants and provide a basis through which the set 
of all possible combinations of implicants (diagnoses)is explored using a branch and bound 
algorithm. This means that unlisted sets of implicants are cumulatively negligible. Al- 
though the extreme case of isomorphism between indicants and implicants is unlikely {and 
probably without clinical meaning), in theory there are 2" - l (the power set) possible 
diagnoses given n binary indicants. Hence some procedure is needed to keep the algorithm 
computationally tractable. 
To begin, absent indicants are noted, and implicants likely to produce them are elim- 
inated. The remainder are inserted into a diagnostic core as a starting point. The core 
greatly reduces the number of possible diagnoses. Having obtained the core, we can 
evaluate its probability. Let D denote a set of implicants each of which is more likely 
than not to produce a given indicant. Then from (21, 
P(&- g~) -< I-I [P~ H (B,k)e"] :'~. (8) 
i 
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where we have used the fact that Q,_ -< 1. Since :,~k = 0 for all i and k (in the case of 
indicants not present), we can write 
Z P(x,, z,) < I1  [l + e~ I-[ - ~'' - (Bik) 1, (9) 
2i k j 
where we have applied a generalization of the ordinary binomial formula. Substituting 
bounding factors yields 
~, P(xi, z,) <- ( rI  Pkb~) [ 1-I (1 + Pkb~)l. 
.:i k~D k~D 
(I0) 
Choose 8 positive such that 
1-I (BJk) ~'' <- a. 
J 
Then the factors in (10) can be bounded and negligible terms eliminated. Terms of the 
form 
1-I [1 - [-[ (~a~)-~i'l 
j k 
will then be as close to their limits as possible, and we can begin the sorting procedure. 
Note that the size of 8 is a function of the number of indicants and, hence, the number 
of possible implicants. 
The bounding factors are sorted by size to a point where they become small as a single 
factor compared to the cumulative probability of indicants. Sets of implicants having a 
sufficiently small collective probability can be ignored. Thus it is necessary to consider 
only those implicants with bounding factor of the order of P(x ] Data). Once specifying 
a diagnostic ore of such implicants, one needs only to consider those diagnoses where 
the bounding factor is non-negligible compared to P(zk). Typically. the most probable 
disease (set of implicants) is the list of the most probable implicants, to the point where 
the implicant probability is about one-half. 
The model treats each patient as a separate, distinct statistical population. Two patients 
may appear equivalent within the framework of information available; this implies that 
the distance between the distributions representing the patients is small. Despite the pro- 
digious variation among patients in clinical appearance, for purposes of mathematical 
characterization we consider the patient-specific joint probability vector which permits 
the estimation of the probability of each combination of indicants. This does not imply 
that each patient has to be studied in sufficient detail to make such calculations ab initio. 
In terms of the Implicant model, given that probability distributions of clinical profiles 
are multidimensional (i.e. vectors), we have provided a relatively low dimensional basis 
for them and means for estimating the components. 
5. GOM MODEL OF DISEASE (PROGNOSIS) 
The Implicant model is primarily diagnostic in that it is designed to provide suitable 
disease definitions for characterizing broadly heterogeneous sets of patients. In this sec- 
tion, we direct attention to prognostic issues in which patients with common (or multiple, 
similar) diagnoses are analyzed to detect extreme possible homogeneous subgroups. The 
purpose is to further efine disease definition, thereby increasing the precision with which 
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patients can be described. If the Implicant model is regarded as prescriptive, then the 
GOM model introduced here is descriptive. 
We begin by introducing the concept of a disease pure type. A pure type is interpreted 
as a clinically distinct, significant representation f a fully developed, uncomplicated dis- 
ease: a clinical type in isolation from all others. In conventional nosological terms, a pure 
type may be the "'classic textbook case" cited earlier; alternatively, it may represent a
less common but noteworthy pattern of illness. The textbook definitions of disease, dis- 
tilled from clinical observation and scientific research, may be thought of as subjective 
pure types. The GOM model provides a way of deriving objective, data-based efinitions 
of pure types. 
A set of pure types equates a post-diagnostic disease state with a set of nonoverlapping 
clinical markers representing the range of observed isease manifestations within the data. 
As a concession to the expected variation among patients cross-sectionally and longitu- 
dinally, we define illness in terms of degrees of involvement ("caseness")  in each pure 
type. Thus patients are not pigeon holed but described by an intergrade vector (g~k) (where 
i indexes patient and k indexes pure type), whose non-negative components sum to one 
over pure types. The (g~k) terms are thus analogous to grades of membership (hence the 
acronym GOM), as defined by Zadeh[20]. and the set of pure types is a fuzzy partition[14]. 
In the sense that a set of pure types can be used to describe a disease course, they may 
be thought of as representing the clinical spectrum of a disease[l]. 
For purposes of explicit disease definition, we impose a probabilistic structure on the 
pure types. We use i to index patient, j to index indicant, m to index indicant outcome 
and denote by p;j,,, the probability that the ith patient will manifest he ruth outcome for 
the j th  indicant. Then the GOM model is represented by 
Pijm = Z g i l ,~k jm/E  gik Z ~.kj .... (11) 
k k m 
where the sum over outcomes for a given indicant-pure-type combination is constrained 
to be 1. The X.kj,,, term represents a measure of the association between thejth indicant 
and the kth pure type: the term ~,,,, Xkj,,, in the denominator of (11) is called a question 
relevance factor and functions as a weight that variablej  has in determining pure-type k. 
These have been included in the model because it is intuitively reasonable to assume that 
indicants will vary in the clinical significance they have in describing patients. If the 
relevance factors are constrained to be unity, the resultant case is a simple GOM 
model[22]. 
Maximum likelihood estimates of the gi~. and )tky,,, parameters are obtained by solving 
the likelihood function, which is given by 
L = I-[ I-[ f I  (p,J~)~'"', (l'_l 
i j m 
where the p;;,,, are defined in (1 I), and where .riy,, is an indicator andom variable equal 
to 1 if the ith patient manifests the ruth outcome of the jth indicant; otherwise, xii,n is 
zero. Earlier versions of the GOM model assumed a Poisson distribution over outcomes 
for a given indicant[14, 21, 22]. The revised model presented here assumes a multinomial 
distribution. 
The GOM model defines disease in terms of a partition of pure types; these are defined 
by the probability distribution evaluated over all outcomes for each indicant. Thus a pure 
type is defined as a set of probability distributions. Given a set of patient data, the pure- 
type partition represents the sharpest possible set of disease definitions needed to "ex- 
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plain" the data: the observed clinical spectrum. Patients are described in terms of their 
degrees of involvement in each of the pure types. The disease definitions are derived and 
expressed in a precise quantitative way and are used in a similar fashion to describe 
patients. 
The GOM model assumes that indicants are conditionally independent given the pa- 
tient's intergrade vector. Hence many indicants can be used to derive pure-type definitions 
and patient descriptions. In addition, by assessing indicant data longitudinally, one can 
obtain a numerical and graphical portrayal of individual patient clinical trajectories. This 
permits elucidation of types of trends (reversible and irreversible) and stages in the course 
of an illness, corresponding to sequences of intergrade vectors. In this way. the clinical 
spectra of disease are explicitly defined. 
5. I. An application of the GOM model 
in this section, we present an application of the GOM model to a preliminary clinical 
study of a data base describing a set of patients with Systemic Lupus Er.vthematosus 
(SLE). This is a disease characterized by a lengthy, variable course, with protean clinical 
manifestations, and of uncertain etiology and prognosis: it is currently regarded as one 
of the most challenging aspects of medical and clinical research[23]. Although rarely fatal 
if treated, SLE is nonetheless potentially disabling. Physicians treating it can expect o 
see patients repeatedly and to have to confront difficult decisions about treatment. Hence 
modeling the course of SLE can provide insights useful for rational therapeutics[24]. 
Data were obtained for each of 64 patients on 45 clinical measures. All patients were 
under the continuing care of the Multipurpose Arthritis Center at the University of Con- 
necticut Health Center. Most patients were seen on more than one occasion, so that the 
unit of observation is referred to as a patient date; there was a total of 277 patient dates. 
The variables comprised a broad range of clinical phenomena. These included several 
measures of blood chemistry (e.g. ANA titer), therapeutic status (prednisone dose) and 
measures of systemic involvement characteristic of SLE {joint swelling, alopecia, etc.). 
A cluster analysis was performed on the data, as an exploratory data analytic technique 
and in order to obtain initial approximations to the nature of the pure types. The clustering 
model used for this purpose was the ditto algorithm[25]. This technique is a robust pro- 
cedure, specifically designed to handle categorical variables. We have modified the al- 
gorithm to insure a minimum cluster size. This was necessary to deal with the large number 
of clusters that were observed when singleton clusters (one observation) were permitted: 
in this instance, the 277 observations generated 60 clusters. (This suggests the patient 
heterogeneity and clinical variability characteristic of SLE.) 
When minimum cluster size was set at 20, six clusters were formed. The structure of 
these clusters was heuristically validated by a split-sample analysis. Accordingly, the 
patient assignments for the six-cluster partition were used as the starting points for a GOM 
analysis. Initial degrees of involvement were set to 1.0, corresponding to duster mem- 
bership; the other elements of the intergrade vector were set to zero. Initial estimates of 
the Po,- terms were obtained from within cluster frequencies, and initial question relevance 
factors were set to 1.0. 
Examination of the six-pure-type partition indicated that one pure type was redundant, 
so that the analysis was modified to generate partitions of sizes four and five. The like- 
lihood ratio test statistics howed a significantly better fit for the five-pure-type partition 
over the four-pure-type partition; however, there was negligible improvement in moving 
from five to six pure types. Hence the results for the five-pure-type model are presented 
here. 
Figure 1 displays a portion of the output giving the pure-type definitions, showing 
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MEASURE 10 ABDOMINAL PAIN 
OUTCOME FREQ TYPE 1 TYPE 2 TYPE 5 TYPE ~ TYPE 5 
NORMAL 0.96 100.00  89 .49  100.00  91 .03  99.96 
ABNORMAL 0 .04  0 .0  10.51 0.0  8 .97 0 .04  
qRFS: 1.0159 0.9995 1.0257 1.0008 0.9542 
MEASURE 11RAYNAUDS PHENOM 
OUTCOME FREQ TYPE 1 TYPE 2 TYPE 3 TYPE 4 TYPE 5 
NORMAL 0.90 66 ,05  100.00  100.00  100.00 80 .~ 
ABNORMAL 0.10 33.95 0.0 0.0  0.0 19.56 
QRFS= 1 .0383 1.0356 0 .9759 1 .0405 0 .8569 
MEASURE 12 SEIZURES 
OUTCOME FREQ TYPE 1 TYPE 2 TYPE 3 TYPE 4 TYPE 5 
NORMAL 0 .99  100,00  100,00  100,00  100.00 88 .23  
ABNORMAL 0.01 0 .0  0 .0  0 .0  0 .0  11.77 
QRFS, 1 .0016 1.0225 0.9981 1.0443 0.8908 
Fig. I. Sample pure-type det]nitions from Systemic Lupus Erythematosus study Isee text). 
probability distributions over outcomes for three of the 45 indicants used in the data base. 
These probability distributions are interpreted as follows. Referring to Fig. 1. an individual 
with degree of involvement of 1.0 in pure-type 5, for example, would have probability of 
0.8044 (or 80.44% as shown in the figure) of not manifesting Raynaud's phenomenon. On 
the other hand, this individual would have a probability of 19.56% of presenting with 
Raynaud's phenomenon. For an individual with degree of involvement 1.0 in pure-type 
1, these probabilities are, respectively, 66.05 and 33.95 (c~). Pure-types 2-4 do not manifest 
Raynaud's phenomenon. 
Using the probability distributions of the kind exemplified in Fig. I (together with 
appropriate distribution moments uch as means and standard eviations! and the QRF 
terms, it was possible to characterize the pure types, in previous analyses of chronic 
disease data bases, ~e noted that pure types could generally be ordered in terms of mean 
severity of symptomatology or degree of illness, in this case, we noted several parallel 
pure types, representing distinct but equivalent degrees of illness manifested in different 
systemic involvements. 
The pure types in Fig. 1 correspond to increasing degrees of disease activity. Thus pure- 
type 5 represents the most active disease; in tact, this type corresponds closely to the 
typical SLE flare type. featuring joint involvement (pain and swelling), rashes and a high 
ESR (sedimentation rate)J23]. Pure-type 4 is somewhat less active than pure-type 5, but 
clinically significant notwithstanding. Pure-type 3represents a moderate degree of disease 
activity, and pure-types 1and 2 correspond to relatively inactive, but not totally quiescent 
disease. Figure 2 shows the intergrade vectors for several of the patients in the study. 
The first four columns in Fig. 2 show, respectively, observation number, patient identifier, 
patient visit number (i.e. patient-date number for the given patient) and the patient's age 
in years at the time of visit. The next five numbers are the components of the patient's 
intergrade vector for the given patient date or visit. 
The next to last column gives the Shannon entropy for the patient's intergrade vector: 
i.e. for the ith observation, the entropy E'i is given by -~7~;, gi~ log ~,.eik. This number 
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PAT TYPE i TYPE 2 TYPE 5 TYPE 4 TYPE 5 ENT 
98 2~ 2 24 .20  0 .326  0 .0  0 .676 0 .0  0 .0  0 .630 10100 
99 24 3 24 .45  0 .0  0 .221 0 .716 0 .0  0 .064  0 .748 00100 
100 25 1 35 .95  0 .210  0 .069 0 .292  0 .430 0.0  1 .234 00010 
101 25 2 36.21 0 .0  0 .093  0 .0  0 .634  0 .273  0 .864 00010 
102 25 3 36 .40  0 .179  0.0  0 .085  0 .736 0 .0  0 .744 00010 
103 25 4 36.67 0 .522  0 .0  0 .106 0 .372  0 .0  0 .945 10010 
10~ 25 5 36 .99  0 .256 0.0  0.131 0.613 0.0  0 .915 O00lO 
105 26 1 3~.71 0 .409 0 .189 0 .254  0 .081 0.066 1 .412 10000 
106 26 2 35.00 0.0 0.49~ 0.376 0.0 0.130 0.981 01100 
107 26 3 55 .32  0 .0  0 .339 0 .660 0 .0  0 .0  0 .641 01100 
I08 26 4 35.49 0.0 0.378 0.287 0.225 0 . I I0  1.304 01000 
109 26 5 35.67 0 .218 0 .597 0 .0  0 .185  0.0  0 .952 01000 
II0 27 I q6.60 0.0 0.0 0.154 0.510 0.336 0.998 00011 
iii 27 2 47.38 0.0 0.0 0.378 0.315 0.307 1.094 00111 
112 28 1 26.71 0.277 0.0 0.528 0 .0  0 .196 1 .012 00100 
113 28 2 27 .09  0 .0  0 .418 0 .447 0 .0  0 .134  0 .99~ 01100 
114 28 3 27.36 0.381 0.0 0.455 0.0 0.161 1.020 I0100 
115 28 4 27.94 0.17~ 0.0 0.575 0.179 0.072 1.119 00100 
116 28 5 28.17 0 .155  0.0  0 .~44 0.0  0 .0  0 .432 00100 
117 29 1 44 .07  0.2S8 0.0  0 .712  0 .0  0 .0  0 .600 00100 
118 29 2 44.27 0.305 0.0 0.183 0.354 0.158 1.332 10010 
119 29 3 44.51 0 .261 0 .288 0 .244  0.207 0 .0  1 .379 00000 
120 29 4 44 .78  0 .280 0 .0  0 .136 0 .584  0 .0  0 .942 00010 
121 29 5 45.01 0 .376 0.0  0 .057 0 .587 0 .0  0 .802 10010 
122 50 1 52.46 0.118 0.0 0.353 0.0 0.529 0.957 00101 
123 30 2 52.66 0.0 0.0 0.0 0.0 1.000 0.000 00001 
12q 30 3 52.69 0.0 0.191 0.0 0.0 0.809 0.488 00001 
125 30 4 52,98 0. I01 0.0 0.537 0.0 0.563 0.955 00101 
126 50 5 55.15 0.0 0.0 0.776 0.0 0.224 0.532 00100 
Fig. 2. Sample patientintergrade v ctors from Systemic Lupus Erythematosus studyIseetext) .  
indicates the extent to which a patient is a mixed type, having significant degrees of 
involvement in more than one pure type. The larger the entropy Ei, the more the patient's 
condition is described by more than one pure type. If a patient has degree of involvement 
1,0 in one pure type, and zero in all others, then Ei = 0,0; E~ is bounded above by 1.6094. 
The final column in Fig. 2 is a pseudocrisp ortrayal of a patient's intergrade vector. 
The pattern features a binary string of length 5, with a 1 in the kth position denoting 
significant degree of involvement in the kth pure type. For Fig. 2, significant was arbitrarily 
defined to be greater than or equal to 0.3, In practice, this cutoff point can vary over pure 
types and often corresponds to the sum over patients of degrees of involvement in each 
pure type, denoted by Sk; e.g. for the kth pure type, Sk = ~,~ g;k. The entropy and pattern 
columns in Fig. 2 provide means for an exploratory data analysis of the output of a GOM 
run, as well as an informal indicator of trends within a patient's history. 
Examination of patient intergrade vectors provides further insight into the nature of 
the pure types. We can distinguish four levels of disease activity in SLE patients; active 
disease (or clinical flare), preflare disease (increasing disease activity), post-flare disease 
(decreasing disease activity) and inactive disease (negligible clinical activity). These are 
general attributes of the pure types, deduced from consideration of patient indicant profiles 
and intergrade vectors. The transition among intergrade vectors was not such that the 
disease course necessarily follows the path (I. 2) ---, (3) ----, (4) --~ (5) ~ (1, 2). where, for 
example, the notation (3) here means a high degree of involvement in pure-type 3. Instead. 
a variety of transition paths were observed across patients, suggesting the variability in 
the clinical course of SLE. 
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Patients with moderate disease activity generally showed a large entropy values for 
the appropriate visit. Patients with very active or very inactive disease generally displayed 
low entropy values. An increase in entropy generally preceded a change in disease activity: 
i.e. transitions were spread over several intervening pure types, rather than manifest in 
abrupt changes from one pure type to another. 
A typical patient history is illustrated in Fig. 3, which plots the degrees of involvement 
in each pure type by age at visit for patient 30 (cf. Fig. 2). The graph has been constructed 
so that the sequence of degrees of involvement in each pure type is plotted as a sequence 
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Fig. 3. Graphical representation f intergrade vectors (by age) for patient in Systemic Lupus Erythematosus 
study (see text). The asterisk denotes clinical flare. 
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The sequence of degrees of involvement have been superimposed to appear on top of 
each other, in increasing order of disease activity: the bottom line in Fig. 3 shows the 
patient's uccessive degrees of involvement in pure-type 1, the second line the successive 
degrees of involvement in pure-type 2. etc. 
At initial examination, this patient manifests moderate but increasing disease activity. 
A clinical flare is observed 10 weeks later and continues for roughly 10 days, after which 
disease activity begins to subside. At subsequent visits, further attenuation i disease 
intensity is noted: these correspond to a decrease in the slope of line 5 in Fig. 3. and a 
simultaneous increase in the slope of line 3. This patient has manifested a classic SLE 
flare pattern. 
It should be emphasized that the results presented here represent our initial effort to 
analyze an SLE data base. Further research is currently being performed using many 
more clinical variables and data covering a longer average period time of observation per 
patient han this data base allows. The average time span per patient for the data base 
described here is 1.07 years, with a maximum of 2.50 ,,ears. Before model results can be 
used to derive generalizations concerning the nature of both the clinical spectrum and 
clinical course of SLE. much more extensive data analysis is needed. 
6. DISCUSSION 
In this paper, we have stressed the concept of disease definition and have indicated 
its crucial immediate relation to the formalization of explanatory and predictive clinical 
hypotheses. Without a functional disease definition, the clinical evaluation and treatment 
of patients would be impossible. The models presented here represent attempts to quantify 
disease definition and to place it on a logical, rigorous base. In addition, our emphasis 
has been on global models of disease: that is, modeling the entire disease process, as 
reflected in the many variables used by physicians to describe patients. 
The operational principles of the implicant and GOM models involve the specification 
of homogeneous subsets of patients. (A set of indicant data is homogeneous if the relevant 
clinical variables are identically and independently distributed, or can be so transformed.) 
These subsets may represent different diagnoses or different illnesses in patients with the 
same diagnosis. 
In simplistic terms, clinical activities are usually classified as one of two types, diagnosis 
or prognosis: for example, in decision-theoretic based models. Diagnosis is specification 
of the disease label causally attributable tothe patient's condition: prognosis loosely refers 
to treatment allocation. The demarcation point between diagnosis and prognosis may be 
a fuzzy one, since even a solely palliative treatment regimen (embarked upon. for example. 
in a patient whose diagnosis is not specified, but whose indicants may require immediate 
response) may influence a disease course. 
We have chosen to group these clinical evaluative tasks under the unifying concept of 
patient management. As the clinical evaluation proceeds, and as the illness progresses 
(perhaps with some kind of intermediate herapeutic ntervention), the patient's disease 
is defined in increasingly precise, sensitive and specific terms. In an independent context, 
physicians discussing SLE have emphasized this same approach: 
We are optimistic about further apid progress in recognition and management of SLE. 
We doubt that progress in management will occur as the result of the discovery of a 
dramatic new therapeutic agent. Rather. we expect continued improvement from the 
present level as we learn to recognize specific patterns of disease common to groups 
of people and also individual patients as unique within the groups, and to prepare 
therapeutic regiments adapted to their particular needs and problems. [26, p. 182] 
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In"practica, we have found the Implicant model useful in partitioning heterogeneous, 
prediagnostic patient data sets. This may be an attempt o establish formal diagnoses or 
a de facto screening procedure. The GOM model is more useful in circumstances where 
longitudinal data are available and where patients are assumed to have a common un- 
derlying diagnosis. The pure types are provided meaning and patient trajectories more 
interpretable if there is a reference point: i.e. the global diagnosis or disease label. 
Conventional cluster analyses applied to patient data bases is the most frequently ap- 
plied method for identifying subgroups for purposes of detecting, if not defining, dis- 
ease[27]. Sometimes this is an effective technique[28], in general, however, these methods 
do not resolve the issue of heterogeneity among patients, but rather partition it into discrete 
groups. By assuming zero-one membership functions, the issue of hypothesis generation 
is not dealt with since the clinician is still required to account for within cluster variation. 
A comparison of cluster and GOM partitions has shown that the latter are more specific 
and more sensitive with respect o changes in clinical course[14]. The utility of both the 
Implicant and GOM models has been documented[13. 14, 21, 22]. The validity of the 
Implicant model is manifest in its ability to quantifiably detect new diseases in the manner 
articulated by Warner, as cited earlier. The validity of the GOM model is seen in comparing 
the objective pure types described in [21] with the subjective pure types discussed in [29]. 
These latter citations indicate that expert clinical opinion is crucial in validating the 
results of the Implicant and GOM disease models. The models provide new data for the 
clinicians: thus interpretation and subsequent hypothesis generation are still in the domain 
of the physician. 
The Implicant and GOM models are related to certain statistical procedures. The lm- 
plicant model is consistent with the latent class model of Lazarzsfeld. as noted briefly 
earlier. Latent structure analysis hypothesizes the partitioning of a set of individuals in 
such a ~ay that, within a class, subject responses to a set of items (discrete variables) 
are independent: his is the concept of local independence. The GOM model displays a 
certain resemblance to factor analysis, which models the covariance structure of a set of 
continuous variables in terms of a smaller set of hypothetical, unobserved measures. 
Certain sampling considerations are common to all these procedures. These arise in 
deriving estimates of model parameters and generally concern the set of indicants litem 
sampling) and the set of cases {patient sampling). In theory, the implicant model is in- 
variant over patients, but not over indicants, since inclusion of additional indicants may 
suggest new implicants that need to be considered. The selection of an indicant protocol 
is done by clinicians. However,  they are encouraged to be "'generous," since redundant 
indicants will not necessarily ield additional implicants, and one seeks the most complete 
disease definition (diagnosis) possible. 
The GOM model variation across cases is reflected in the patient intergrade vectors. 
It is reasonable to expect the disease definitions (the pure types) to be consistent over 
samples of cases{30]. Even if additional indicants are added to the protocol for subsequent 
reanalyses, these will serve to refine the pure-type definitions, most likely leaving the 
original pure-type-indicant relationships unchanged. This is a consequence of the con- 
ditional independence assumption. The invariance of the pure-type definitions across sam- 
ples suggests the utility of the GOM model as a validating and unifying mode of analysis 
for explaining, for example, differences among patients across providers or across treat- 
ment regimens. 
Both models are currently undergoing further development, The predictive properties 
of both models needs to be investigated. To this end, we are currently expanding the 
study of SLE described in Sec. 5.1. As a substudy of this, we are developing a micro- 
computer based consultation system for SLE patients at the Multipurpose Arthritis Center 
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at the University of Connecticut Health Center. This will enable physicians tO update an 
individual patient's clinical profile and obtain estimates of the patient's hort-term course, 
following the latest observation and therapy. This particular system is heavily oriented 
towards graphics, so that the clinician's interpretive tasks are simplified. This is a prelude 
to a formal study of the use of a GOM-based algorithm for clinical decision-making. The 
Implicant model results presented here represent an extension of the model first presented 
in [31] and the introduction of a computational procedure. For the GOM model, we are 
developing means for relating partitions of pure types based on variables from different 
clinical domains (e.g. neurological, physiological, etc.), levels (subcetlular to multisys- 
temic) and other varied perspectives that define a taxonomy of clinical indicants (for 
example, etiological and secondary characteristics of disease). 
Another potentially useful application of the GOM methodology lies in the area of 
applied judgmental research; see, for example, [6] and [I0] cited earlier. Although much 
work has been done on the use of subjective probabilities in clinical decision tasks, little 
has been done concerning assessing a physician's operational understanding and inter- 
pretation of such concepts of "'degree of sickness" and "at risk"[16, 27]. (However, it 
is worth noting that at least one clinician has defined a subjective measure of degree of 
disease activity in the analysis of SLE[24].) 
To this end, the GOM model provides a base for portraying a clinician's experiential 
beliefs about a disease and associated clinical spectrum. We are studying the use of a 
subjective, a priori defined partition of pure types to be used as input in determining a
posteriori patient descriptors. Clearly, such a subjective-based construct will provide a 
great deal more information than subjective probabilities, especially when the latter are 
derived in a context unfamiliar to most clinicians. (The genesis of this paradigm was the 
comparison, noted earlier, between subjective and objective pure types: cf. [21] and [29].) 
Results of this kind of analysis may be useful in explaining variation in physician practice 
patterns (especially if characteristics of the patient's insurance coverage are included in 
the indicant protocol). 
In sum, these models provide a fertile base for further research. They have also dem- 
onstrated to date a useful way of empirically and rigorously defining disease through the 
joint efforts of clinicians and mathematical modelers. 
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APPENDIX  A 
In this section, we present an example to illustrate some of the theoretical and computational 
aspects of the Implicant Model. The patient data used in this example represent HLA serotypes 
developed from certain families studied in the 1977 International Histocompatibil ity Workshop held 
in Oxford, England. A portion of the raw-data matrix is given in Table AI" a 0 denotes lack of an 
indicant (equivalent here to lack of reaction), a I denotes the presence of an indicant and an asterisk 
denotes missing data. There were I03 patients, each assessed for a total of 178 indicants. 
It was necessary to provide input for use in deriving the posterior implicant probabilities: spe- 
cifically, values of qj~, where j  indexes indicants, k indexes implicants and where qjk is defined as 
the (conditional) probability of observing the absence of indicantj  given that implicant k is the only 
one present. In this example, simplified estimates were obtained using expert judgment. 
Table A[. Sample raw data matrix, indicants 1-15, 164-178 (see textl 
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Table A2. Intermediate calculations for use in computing posterior implicant probabilities for padent 11 (~ee 
text) 
Z PR(Z) BF(Z) PIINJM ERSUM 
0000010 0.68869E-46 0.32488E-08 0.68869E-46 0.0 
I000000 0 . 17085E-36 0.32488E-08 0.17085E-36 0.0 
0100000 0.13640E-56 0.23280E-21 0.17085E-36 0.0 
0000100 0.18922E-73 0.15744E-28 0.17085H-36 0.0 
0010000 0.42359E-77 0.641475-31 0.17085E-36 0.0 
0001000 0.49231E-76 0.64146E-31 0.17085E-36 0.0 
0000001 0.0 0.26135E-33 0.17085E-36 0.0 
i000010 0.63035E-34 0 .I0555E-16 0.63206E-34 0.0 
0100010 0.57953E-55 0.75633E-30 0 . 63206 E-34 0.0 
0000110 0.41716E-65 0.51151E-37 0.63206E-34 0.0 
0010010 0 .i 80 48E-68 0 . 20840E-39 0 . 63206 E-34 0.0 
0001010 0 . 10854E-57 0.20840 E-39 0 . 63206 E-34 0.0 
0000011 0.0 0.84908E-42 0.63206E-34 0.84908E-42 
1100000 0.33427E-45 0.75633E-30 0.63206E-34 0.84908E-42 
i000100 0.53181E-58 0.51151E-37 0.63206E-34 0.84908E-42 
I010000 0.23008E-61 0.20840E-39 0.63206E-34 0.84908E-42 
1001000 0 . 13837 E-60 0 . 20840 E--39 0 . 63206 E'-34 0.84908E-42 
1000001 0.0 0.84907E-42 0.63206E-34 0.16982E-41 
Table A2 displays values of several of the intermediate computational quantities for a given 
patient. It should be noted here that calculations for this example have been undertaken assuming 
seven implicants, This number was chosen from consideration of expert judgment, as well as pre- 
vious analysis of data of this type. The model can handle a much larger number of implicants: 
however, the output format would be very similar to what is presented here. 
In Table A2, the disease combinations (i.e. sets of implicants) are listed in the column headed 
Z. The column headed PR(Z) lists probabilities of the type PIx,.. c.i): see Eq, (6). Bounding factors 
associated with a given implicant or implicant combination appear in the column BFIZI, The PRSUM 
column lists the accumulated total of the P(&. el) terms, summed over implicants: see Eq. {10). 
The ERSUM column lists the sum of bounding factor products for discarded combinations. Recall 
that the combinations are used to create all variations, but most (if not all) may be discarded by 
examining the bounding factors. 
Certain of the key computational steps are also illustrated in Table A2. Note that t~e first search 
for single implicant candidates. This means that binary strings of length 7, with only one nonzero 
component, are evaluated initially. Note further that they are listed (i.e. sorted) in decreasing order 
of their bounding factors, There are two indications of the presence of significant implicants: the 
magnitude of the bounding factor with respect o the PRSUM and significant increases in the mag- 
nitude of the PRSUM. 
Examination of Table A2 reveals that only implicants 1 and 6 are initial diagnostic possibilities, 
Further exploration will therefore be confined to disease variations containing these implicants. All 
other single implicant diseases were negligible and were therefore "checked oft":  i.e. eliminated 
from further consideration as diagnostic possibilities. Thus the algorithm will not bother to explore 
variations of the disease 0000100, since the bounding factor for implicant 5 was negligible. However. 
it is possible for an implant (or. in some cases, a disease) to reappear on the list if the bounding 
factor for a combination of candidate implicants--including the one checked off - - is  not negligible. 
Restricting attention to implicants 1 and 6, then, two implicant diseases are listed (again. in 
decreasing order of bounding factors), following the single implicant disease candidates. Note that 
the bounding factor for a combination of implicants is the product of the component implicant 
bounding factors: thus the bounding factor for disease 1000010 is the product of the bounding factors 
for diseases 1000000 and 0000010, as can be seen in Table A2. Following evaluation of single im- 
plicant diseases, the diagnostic ore consists of implicants 1and 6. The bound of the total probability 
of discarded implicant combinations (the complement of the core) is listed in the ERSUM column, 
The list is comprised of successively more complex diseases (that is, larger numbers ofimplicants) 
as the search procedure investigates disease variations. (Table A2 only illustrates everal two ira- 
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Table A3. Posterior implicant probabilities for selected patients 
P(la~plican~ k) fo~ k = 
Patient 1 2 3 4 5 6 7 
Ii !.00 0.00 0.00 0.00 0.00 1.O0 0.00 
20 0.00 1.00 0.00 0.00 0.05 0.95 0.00 
34 0.00 0.00 0.00 0.53 0.00 1.00 0.00 
55 0.50 0.00 0.00 0.00 1.00 0.08 0.00 
76 0.00 0.88 0.12 0.00 0.00 1.00 0.00 
82 0.00 1.00 0.00 0.00 1.00 0.90 0.00 
i01 0.00 0.00 0.00 0.00 0.00 1.00 0.00 
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plicant disease combinations: the full list considered 15 two-implicant-disease combinations, nine 
three-implicant-disease combinations and one four-implicant-disease combination. Only variations 
containing implicants I and/or 6 were noteworthy.) In the example of Table A2. calculations were 
halted after examination of one probabilistically negligible four-implicant disease, and the diagnosis 
for this patient was effectively complete. Selected diagnostic probabilities are listed in Table A3. 
for each of several patients. These posterior empirical Bayesian implicant probabilities were ob- 
tained by dividing the prior indicant probabilities by the total probability of the indicants. Pry,), 
where this probability is obtained by summing the joint probabilities P(vi, -,J over the implicants 
retained in the diagnostic ore. Thus one may write 
P(:i!.v,) = PLvi. ::i)/PI&). 
This is derived by a straightfor~ ard application of Bayes's theorem to all multiple implicant diseases. 
The final set of diagnoses for each patient (the most likely set or" implicants) is not listed, but 
in most cases can be determined by inspection: see Eq. (3). For example, for patient 11, the most 
probable combination is 1000010 li.e. implicants I and 6 present). The probability of this combination 
is given by 0.63055E-34/0.63206E-34 = 0.9973, while the probability of disease 1000000 (i.e. im- 
plicant one only) is 0.0017/0.63206 = 0.0027. 
These implicants are closely associated with factors that cause rejection of transplanted organs. 
By matching patients to implicants, we can assess the probability that they are good candidates 
for transplantation. 
APPENDIX B 
This section presents a streamlined version of GOM model output. The material should help 
illustrate the concepts of pure types and degrees of involvement v.hich are crucial to the GOM 
model formalization. Although the example here is artifactual, the analogies to the example given 
in the text are straightforward. 
Consider a three-pure-type, three-indicant model. Suppose the three indicants are each measures 
of blood chemistry, with the property that. with respect o some hypothetical disease, low values 
are normal or represent a relative lack of pathology, while high ;alues are abnormal, Moderate 
values are just that; moderate, possibly suggesting a change in disease activity (e.g, the patient is 
getting better or getting worse, depending on the direction of change from high to moderate or low 
to moderate, respectively). The pure-type definitions are given in terms of these three values or 
outcomes (low. moderate and high) for the three indicants. Simple pure-type definitions are illus- 
trated in Table B I. 
Based upon examination of Table BI, we see that pure-type I is consistently (i.e. across all three 
indicants) low in terms of expected or mean outcome. For example, this type will, on average, 
have a probability of 0.8 of manifesting a "'low'" outcome on indicant 1, and 0.2 of manifesting a 
"moderate" outcome. Such a type will never manifest a "'high" outcome. On the other hand, pure- 
type 3 has a consistently high probability of presenting with "'high" or pathologically abnormal 
values on these indicants. Pure-type 2 represents a moderate degree of disease activity. 
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Table B I. lndicant outcome probability distributions for hypothetical three-indicant, three-pure-type GOM 
model 
L-~li cant Pr (Outcome for pure type k), k = 
Outcrme 1 2 3 
Blood LG¢ 0.8 0.4 0.0 
Chemistry 1 M£IERATE 0.2 0.4 0.4 
HIGH 0.0 0.2 0.6 
Blood LCW 1.0 0.0 0.0 
Chemistry 2 MDDERATE 0.0 0.8 0.i 
HIGH 0.0 0.2 0.9 
Blood IX~ 0.8 0.5 0.0 
Chemistry 3 M~3ERATE 0.2 0.3 0.2 
HIGH 0.0 0.0 0.8 
Thus, in formulating pure type characterizations from GOM model output, it is necessary to 
recall that pure type definitions are given in terms of probabilities. Each of the numbers in Table 
BI is a probability, and for each of the nine indicant-pure-type combinations shown, the three 
numbers represent a probability distribution. The entire pure-type definition is based upon the set 
of all such distributions, evaluated over all indicants, for each pure type. (In order to simplify the 
illustration, we have omitted consideration of the QRF terms described in the text: these would 
assist in evaluating pure types by specifying indicants that are not relevant o an individual pure- 
type definition.) 
A partition of pure types may be regarded as a set of clinical disease patterns which "'explains" 
the variation among patients in indicant profiles. Patients do not necessarily correspond exactly to 
any of the pure types, just as patients may not correspond closely to classical textbook disease 
definitions. The extent o which a patient corresponds to a pure type is measured by his degree of 
involvement in that pure type. The degree of involvement is a number between zero and one 
inclusive; the larger the number, the more the pure type describes the patient's condition. This is 
illustrated in Table B2. 
Table B2 displays the degrees of involvement for a hypothetical patient in each of the three pure 
types shown in Table B 1. The five time points correspond to a sequential series of examinations 
or clinic visits over time. This patient, when first seen, sho~ed asymptomatic disease activity. 
However, from time 2 to time 3, his clinical condition deteriorated, as reflected by decreasing 
degrees of involvement in pure-type I and increasing degrees of involvement in pure-type 2. Finally, 
at time 4, the activity peaked (corresponding to maximum degree of involvement in pure-type 3). 
and subsided at time 5 (decreasing degree of invoLvement in pure-type 3, and increasing degree of 
involvement in pure-types 1and 2). 
Because patients are described quantitatively in this way, the GOM model may prove more 
sensitive and specific in decision making schema than conventional disease models. Investigation 
of such predictive attributes of the model are underway. 
Table B2. Degrees of involvement for hypothetical patient in each of three pure types shown in Table B I. on 
each of five time points 
Degree of I..-~o].v~elYc ~ Pure Type k, k = 
TL,~e 1 2 3 
1 0.95 0.05 0.00 
2 0.80 0.20 0.00 
3 0.50 0.40 0.i0 
4 0.20 0.20 0.60 
5 0.50 0.40 0 .i0 
